Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.54 |
| ▸ | ASPH | Q12797 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | OXTR | P30559 | 1/20 | 0.42 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3881337 | 0.81 | TRPV1 (0.65) | TRPV1OXTRAVPR1A | |
| SCHEMBL28255301 | 0.80 | P4HTM (0.47) | TRPV1 | |
| SCHEMBL4558359 | 0.79 | TRPV1 (0.60) | TRPV1 | |
| SCHEMBL4355234 | 0.78 | ASPH (0.46) | TRPV1ASPH | |
| SCHEMBL4182641 | 0.78 | CNR2 (0.49) | TRPV1 | |
| SCHEMBL4179855 | 0.77 | TRPV1 (0.50) | TRPV1 | |
| SCHEMBL5313203 | 0.76 | CNR2 (0.53) | ASPH | |
| SCHEMBL6430247 | 0.76 | CYP2A6 (0.49) | TRPV1SCN5ASCN9A | |
| SCHEMBL4472961 | 0.76 | TRPV1 (0.51) | TRPV1SCN5ASCN9A | |
| SCHEMBL904498 | 0.75 | TRPV1 (0.46) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199965-B2 | Benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG CO., LTD. (KR) | 2015-12-01 | — | — | US | disclosed |
| EP-1861387-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | DAE WOONG PHARMA (KR) | 2014-04-16 | — | — | EP | disclosed |
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-01-15 | — | — | US | disclosed |
| EP-1861387-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006080821-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | TRPV1, TRPA1, BDKRB2 | TRPV1 1/4885ASPH 3870/4885SCN5A 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.